-+ 0.00%
-+ 0.00%
-+ 0.00%
Hanx Biopharmaceuticals partners with Ditu Zhiyuan on AI-driven cancer drug research
Share
Listen to the news
Hanx Biopharmaceuticals partners with Ditu Zhiyuan on AI-driven cancer drug research
  • Hanx Biopharmaceuticals entered a research cooperation agreement with Suzhou Ditu Zhiyuan Biotechnology on November 11, 2026.
  • The collaboration will use Ditu Zhiyuan’s Meritudio BioAI cloud platform for translational and clinical research on Hanx’s proprietary oncology drug pipeline.
  • AI-driven data analysis will support preclinical research planning and clinical development strategies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12414431), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending